Abstract

BackgroundThe risk of adverse cardiovascular events and mortality associated with testosterone replacement therapy is controversial. The purpose of this report was to evaluate the effect of testosterone replacement therapy (TRT) in men with secondary hypogonadism on the risk of myocardial infarction (MI), stroke (CVA) or all-cause mortality.MethodsA retrospective cohort study was conducted using the Cleveland Clinic’s electronic health record. Men ≥40 years of age, with at least two testosterone levels < 220 ng/dL, with one level obtained between 7 am and 10 am, were identified. Men with primary hypogonadism, secondary hypogonadism related to overt hypothalamic pituitary pathology, human immunodeficiency virus infection, metastatic cancer, and select contraindications to TRT, were excluded. Men exposed to TRT were matched to controls that were not exposed. A survival analysis was performed on the composite outcome of MI, CVA, or all-cause mortality.ResultsOne hundred sixty-five patients exposed to TRT (treatment group) were matched with 210 not exposed to TRT (comparison group). The prevalence of established cardiovascular disease (CVD) was 20.0% in the treatment group vs. 17.1% in the comparison group (P = 0.478). The median [interquartile range (IQR)] age (years) and BMI (kg/m2) were 55 (49, 62) and 35.6 (32.1, 40.1) in the treatment group, and 55 (49, 61.7) and 36.3 (32.1, 40.8) in the comparison group, respectively. There were 12 (7.3%) events observed in the treatment group, and 16 (7.6%) in the comparison group. The median time (years) to the composite event was 2.1 (IQR 0.9, 4.6) and 1.8 (IQR 0.6, 3.4) for treatment and comparison groups, respectively. No difference in the risk of the combined cardiovascular endpoint was observed between the treatment group vs the comparison group, hazard ratio (HR) 0.81 (95% Confidence Interval [CI]: 0.38–1.71; P = 0.57).ConclusionIn hypogonadal men with a modest prevalence of established CVD, TRT was not observed to confer a protective or adverse effect on the risk of MI, CVA or all-cause mortality.

Highlights

  • The effect of testosterone replacement therapy (TRT) on cardiovascular risk has been controversial [1, 2]

  • The objective of this report was to evaluate the effect of testosterone replacement therapy (TRT) on the risk of myocardial infarction (MI), stroke (CVA) or all-cause mortality, in men with secondary hypogonadism unrelated to overt hypothalamic-pituitary pathology managed at our institution

  • The 165 patients exposed to TRT were matched with 210 patients not exposed to TRT

Read more

Summary

Introduction

The effect of testosterone replacement therapy (TRT) on cardiovascular risk has been controversial [1, 2]. Many retrospective studies regarding the safety of testosterone replacement therapy in hypogonadal men have been published with mixed results [4–8]. While there have been many prospective randomized controlled trials published recently regarding the benefits of testosterone replacement therapy on sexual function, mood and depression, bone mineral density, and anemia, the cardiovascular safety and the risk of mortality associated with TRT remains unclear [9–12]. The risk of adverse cardiovascular events and mortality associated with testosterone replacement therapy is controversial. The purpose of this report was to evaluate the effect of testosterone replacement therapy (TRT) in men with secondary hypogonadism on the risk of myocardial infarction (MI), stroke (CVA) or all-cause mortality

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.